CompaniesHeidelberg Immunotherapeutics

Heidelberg Immunotherapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (2)
View all

Total Trials

2

As Lead Sponsor

2

As Collaborator

0

Total Enrollment

883

By Phase

PHASE2: 2

By Status

TERMINATED: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
Today
NCT04165122
NCT04539483
Hover over trial bars to see details

Recent Trials

NCT04539483Lead Sponsor
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
PHASE2Terminated
761 participants
Started: Oct 8, 2020 · Completed: May 31, 2023
NCT04165122Lead Sponsor
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection
PHASE2Completed
122 participants
Started: Nov 15, 2019 · Completed: Nov 1, 2021